IntroDuctIon
Gene targeting has provided important insights into fundamental biological processes and the potential to cure genetic diseases. Although the process of homologous recombination (HR) works efficiently in bacteria and yeast, the maximum targeting efficiency achievable in mammalian cells is usually 1 per 10 6 transfected cells [1] [2] [3] . In addition, the targeting vector DNA can integrate randomly by nonhomologous end joining. The preparation of standard targeting constructs is also complicated, requiring several kilobase pairs of genomic DNA for homology arms, which can be expensive and time consuming.
Efforts to improve targeting frequencies have led to the exploitation of double-strand breaks to stimulate recombination. Customizable nucleases such as zinc finger nucleases (ZFNs) have improved the HR rates by logs, such that >1% of cells undergo targeting in some settings [4] [5] [6] . However, genotoxicity due to both on-and off-target cleavage by ZFNs is a potential problem 7 , as is the technical expertise required to design and test custom nucleases. Moreover, repair of the ZFN target-site break by nonhomologous end joining can lead to frequent mutations 4, 8 , as was observed in up to 28% of target alleles in human embryonic stem cells (ESCs) in one study 4 . Moreover, nonhomologous integration of the targeting construct or ZFN expression cassette has also been reported 6 . Assessment of the in vivo cleavage specificity of ZFNs in a complex genome remains an unresolved issue that limits their use.
Adeno-associated virus (AAV) vectors have single-stranded DNA genomes, are efficiently delivered to the nucleus and can be constructed with simple PCR-based methods, making them an attractive alternative for gene targeting studies. Recombinant AAV vectors can efficiently target homologous chromosomal loci and introduce defined sequence changes with high fidelity. Several kinds of changes, including point mutations, insertions, deletions and selectable cassettes, have been introduced in a diverse variety of human cells . Table 1 summarizes many of the various human cell lines and genes targeted by AAV vectors to date. Most of these experiments were conducted on transformed cell lines to elucidate the effect of specific genes involved in signaling pathways [11] [12] [13] . However, AAV has also been successfully used to target primary human cells such as fibroblasts, keratinocytes, mesenchymal stem cells (MSCs), ESCs and induced pluripotent stem cells (iPSCs) at multiple loci including the genes COL1A1, COLIA2, HMGA1, HPRT1, NANOG and KRT14 (refs. 15-18,32) . More recently, AAV vectors have also been used for epitope tagging in a variety of human cell lines 34, 35 , allowing proteins to be studied when expressed from their normal chromosomal locations.
Using the methods described in this protocol, AAV-mediated gene targeting frequencies can vary from 10 − 5 to 10 − 2 . Although a range of targeting frequencies is expected from any technology, there are a number of factors that can affect the targeting frequency of AAV vectors. These include the length of the homology arms 36 , the nature of the sequence change being introduced (deletion vectors target at lower frequencies) 20 , the position of the change being introduced within the homology arms 36 , the multiplicity of infection used 19 , and the proliferative status of the infected cells 37 . Other factors that may affect targeting frequencies but that have not been demonstrated experimentally include the transcriptional state of the target locus, the presence of nonisogenic DNA in the homology arms and the use of unpurified vector stocks. Finally, it should be noted that many experiments require expression of a selectable marker to measure targeting frequencies; if targeted alleles fail to express the selectable marker at adequate levels the apparent targeting frequencies will be reduced.
AAV-mediated gene targeting does have certain limitations, such as the small packaging capacity of AAV (~4.7 kb), the relative inefficiency of targeting silent loci 38, 39 , the inability to target nondividing cells 37 and a potential for random integration 40 . Conventional targeting approaches suffer from some of these same limitations, including random integration 41, [42] [43] [44] , and poor targeting in nondividing cells 45 and at silent loci 44 . It should be noted that the chances of a cell having both random and targeted integrations are minimal when using AAV vectors; in published reports, over 250 targeted clones were screened and only 7 also contained random integrants [15] [16] [17] 19, 32, 46 .
Experimental design
Vector design and preparation. Specific guidelines for vector design depend on the intended application. However, there are some general principles to follow. The packaging limit of AAV vectors is 4.7 kb; therefore, the targeting cassette has to be efficiently designed with the smallest possible genetic elements, and within this constraint the length of the homology arms should be maximized. For example, targeting frequencies were two-to fivefold higher with 3.0 kb of total homology, as compared with 1.7 kb of homology 36 . In addition, the mutation to be introduced should be centrally positioned with respect to the homology arms. Targeting frequencies drop precipitously when one of the homology arms is less than ~100 bp 36 . An advantage of the short homology arms used in AAV vectors is that, unlike the longer arms required for plasmid-based targeting approaches, they can be easily prepared by PCR of genomic DNA. A simplified technique to assemble an AAV targeting vector plasmid using three-way fusion PCR with homology arms and a selection cassette has been described 24 . The protocol described here involves independently amplifying each homology arm and selection cassette. The homology arms and the AAV backbone are assembled in a three-way ligation step followed by ligation of the selection cassette.
AAV-mediated gene targeting methods for human cells
Although a multitude of mutations have been introduced using AAV vectors (see Table 1 ), insertions are clearly favored over deletions. Although the mechanism for this preference is unknown, the effect can be significant, with insertion vectors targeting at more than tenfold higher frequencies over a range of insertion/deletion sizes from 1 bp to more than 1 kb (ref. 20) . As combined insertiondeletion vectors (those designed to both remove genomic DNA and insert foreign sequences) target at intermediate frequencies, this design can be preferable when introducing deletions.
Several typical vector designs are shown in Figure 1 . Many applications require that a gene be knocked out so that it no longer expresses a functional protein. This can be done most easily by inserting a selectable marker and polyadenylation (pA) signal into a coding exon in a way predicted to inactivate the protein (Fig. 1a) . If the gene is expressed at low levels or not at all, the selectable marker cassette must include a promoter. AAV vectors with this design have used promoters such as phosphoglycerate kinase, thymidine kinase and others 22, 23 . Expressed loci can be targeted with a promoter-trap vector such that the chromosomal promoter drives expression of the selectable marker, and an internal ribosome entry site (IRES) element can be placed upstream of the selectable marker to initiate translation 23 . The promoter-trap design has the advantage that most random integrants will not express the selectable marker, increasing the percentage of drug-resistant colonies that are targeted. Typically, the random integration frequency is about tenfold higher than the gene targeting frequency 19, 23 , and this ratio can be higher in silent loci 38, 39 . There are several points to consider in these designs. First, it is preferable to target a downstream exon if possible (not exon 1), because sequences immediately upstream of exon 1 contain the chromosomal target gene promoter and could increase gene expression at random locations when included in a homology ITR   ITR  ITR   ITR  ITR  ITR   ITR  ITR   ITR  ITR  ITR  ITR  Stop x3 Stop x3 (a) For knockout vectors, an exon is disrupted with a promoter (P) or an IRES driving a selectable marker (SM) and flanked by loxP sites (L). Stop codons in all three reading frames (Stop ×3) and a polyadenylation signal (pA) are included outside the loxP sites, so that these remain at the target loci after Cre-mediated removal of the selectable maker and continue to disrupt gene function. The inverted terminal repeats (ITRs) at either end of the vector are shown as hatched boxes. (b) ATG trap vectors include a selectable marker reading frame placed at the target gene's translation initiation codon (ATG), and are most effective if the start codon does not lie within the first exon. (c) For knock-ins, the mutation to be incorporated (*) can be included in the homology arm of the targeting vector, whereas the SM cassette is placed in an adjacent intronic region, flanked with loxP sites. The SM can either be promoter driven or have a splice acceptor (SA) and IRES, followed by the SM. (d) Subtle mutations can be introduced without including any SM cassette by engineering the mutation (*) into the contiguous homology arms.
arm. Second, even though the selectable marker cassette disrupts a coding region of an exon, it can still fail to disrupt protein function. This can happen when a non-essential peptide is encoded by that exon, and exon skipping occurs with splicing out of the transgene cassette 15 . It can be avoided by targeting an exon with a sequence that is not a multiple of 3 bp, such that exon-skipping will produce a frameshift in the coding sequence after splicing. Third, in many instances it may be desirable to remove the selectable marker cassette after targeting. This can be done by flanking the cassette with loxP sites and introducing Cre recombinase to delete sequences between these sites 47 . In this case, the pA site as well as a sequence with a stop codon in all three reading frames should be placed outside the loxP sites (Fig. 1a) , so that these elements continue to disrupt protein function after Cre-mediated transgene deletion 15 . Finally, in some cases it may be possible to knockout a gene by directly inserting a selectable marker reading frame at the chromosomal initiation codon (ATG-trap variant of the promoter trap; Fig. 1b) . The advantage of this approach is that it is extremely rare for random integrants to express the selectable marker, as this requires integration in a transcribed gene upstream of the first coding exon. An AAV vector designed to target the HMGA1 gene by an ATG trap resulted in > 95% of drug-resistant colonies being targeted 17 . It is best to use this strategy when there are 5′ untranslated exons to avoid including chromosomal promoter sequences in the homology arms.
Specific knock-in mutations can also be introduced with AAV vectors. In this case, a loxP-flanked selectable marker cassette is placed next to the mutation being introduced so that both are incorporated into the target locus (Fig. 1c) . Cre-mediated recombination can then remove the selectable marker (including the pA site) and leave behind the desired mutation. It is important to confirm that the mutation was introduced with the selectable marker, as a recombination crossover can theoretically occur between these elements. To minimize the chance of this, the loxP-flanked cassette should be placed as close as possible to the mutation being introduced, keeping in mind that a single loxP site will remain after Cre-mediated deletion, and this could potentially affect gene function if placed too close to a splice junction or other genetic elements. As with knockout vectors, the selectable marker can include a promoter when targeting an unexpressed locus, or use a splice acceptor-IRES element in a promoter-trap strategy when targeting an expressed locus. Both approaches have been used with AAV vectors 21, 22 . In some cases, it may be possible to perform targeting without introducing a selectable marker. This type of vector design is simple, with homology arms flanking the mutation being introduced (Fig. 1d) . As targeting occurs in up to 0.1-1% of the entire cell population 17, 19 , in principle, one can screen ~100-1,000 colonies to identify a targeting event without using a selectable marker. However, this labor-intensive approach is not usually necessary, given the versatility of selectable marker strategies. Instead, this strategy is effective when correcting mutations, and has been used to target several reporter constructs (lacZ 48 , neo 49 , GFP 46 and alkaline phosphatase 9 ), as well as chromosomal genes (GusB (ref. 48 ) and HPRT1 (ref. 9)). HPRT1 is an especially versatile target as it is an Xlinked gene present as a single copy in diploid male cells, and drug selections are available for both HPRT1 -and HPRT1 + cells. In a recent study, the KRT14 gene was successfully targeted in 0.6% of the total cells transduced 32 . Mutant enhanced GFP has been corrected using AAV vectors under nonselective conditions at an efficiency of 0.1% of the entire population 46 , although lower frequencies have been reported in the absence of double-strand break-induced AAV targeting 50, 51 . Single-nucleotide polymorphisms (SNPs) occur at a frequency of 1 per 500-1,000 bp in humans; therefore, they are likely to be present in the homology arms of targeting vectors. Conventional gene targeting studies in mice have shown that the use of isogenic DNA improves targeting frequencies by 20-fold, suggesting that mismatches between the target and targeting construct inhibit recombination 52 . In the case of human cells, a deleterious effect of SNPs on targeting frequencies has not been demonstrated. Several studies have shown that non-isogenic DNA can be used for targeting different human cell lines 53 , including when AAV vectors are used 17 . However, to date no one has directly compared the targeting frequencies of vectors with and without known SNPs in the homology arms; therefore, it is possible that SNPs have an effect. To avoid possible SNP effects, one can amplify the homology arms from the same cell line to be targeted. In addition, to avoid the introduction of PCR errors, we amplify homology arms in three independent PCR reactions, and subclone and sequence three independent products. When the exact same sequence is recovered at least twice, it must be present at a minimum of one target locus allele. Novel SNPs can sometimes be identified in this way and distinguished from PCR errors.
AAV stock production. Wild-type AAV is a defective, nonpathogenic parvovirus that requires coinfection with a helper virus such as adenovirus for establishing a productive infection. Recombinant AAV vectors are derived by replacing the rep and cap genes of wild-type AAV with foreign DNA, which is flanked by the AAV inverted terminal repeats, the only obligatory viral element. The entire vector genome is prepared in a plasmid form along with a bacterial origin and an antibiotic resistance gene, and transfected into human cells during vector production. Stocks are produced by co-transfecting this vector plasmid with additional helper plasmid(s) containing the AAV rep and cap genes and specific adenovirus helper genes into human cells, which then replicate the vector genome and package it into virions. We use helper plasmids pDG (ref. 54) to produce serotype 2 vectors and pDGM3B (ref. 55) to produce serotype 3 vectors (which replaces the AAV2 capsid gene in pDG with that from AAV3B). These plasmids combine the AAV and adenovirus helper functions. Excellent protocols for the preparation of AAV stocks by both iodixanol and CsCl methods are provided by Grieger et al. 56 . They describe a three-plasmid transfection method to generate AAV stocks. Our approach uses a dual-plasmid transfection system, in which both the adenoviral and AAV genes required are included on a single helper plasmid 54 , and the serotype 2 stocks are purified by heparin affinity column; this is followed by desalting 57 . Serotype 2 was the original serotype developed for AAV vectors. However, over 100 different serotypes of AAV have since been isolated from various animal species 58 , and several of these have been used to produce vectors. These serotypes have distinct capsids that use different cellular receptors to transduce specific cell types at markedly different rates. For most of the experiments conducted on cultured cells the AAV2 serotype works well. One notable exception is that the AAV3 serotype transduces human pluripotent stem cells (PSCs) at twofold higher frequencies than the AAV2 serotype 18 , and might be preferred for these applications. Experiments done in our laboratory have also shown a two-to fourfold higher transduction efficiency of ESCs by AAV3 compared with AAV2 serotypes (R.K.H. and D.W.R., unpublished data). Both AAV2 and AAV3 vector serotypes are produced in the same way, except that distinct helper plasmids containing serotype-specific cap genes are used.
Purification of AAV based on CsCl 2 density gradients 59 was originally used to isolate AAV vector particles, and it is still popular. However, CsCl 2 is toxic to cells and must be completely removed before using the stock. We recommend using nontoxic iodixanol density gradients instead 57 , as for many applications the vector can be delivered directly to cells while in iodixanol. It is important to use some form of density gradient purification so that empty virions can be removed from the stock (these have a different density than packaged virions), as these empty virions could bind to cellular receptors and inhibit transduction. Additional methods can be used to further purify vector particles, but these may be serotype specific. In the case of AAV2, a heparin affinity column works well, as the closely related heparan sulfate molecule is the natural cell surface receptor for AAV2. Extensive vector purification is not always necessary, and some investigators have successfully used crude stocks (transfected cell lysates) for gene targeting 22 . Although this saves time, the presence of cellular debris and low titers of crude stocks can decrease transduction frequencies.
Vector stocks can be titered in several ways. The most consistent methods are based on quantifying the number of vector genomes by using Southern blots, dot blots or quantitative PCR. The dot blot and quantitative PCR methods are quicker, but they will not provide any information on the integrity of the vector genomes, which may undergo rearrangements during vector production. Alkaline gel Southern blots are an especially informative way to titer vector stocks 60 , as the genomes are analyzed as denatured single strands. However, in our experience this method can result in degradation and smearing of hybridized bands. Instead, we routinely titer AAV vector stocks by Southern blots of neutral gels, taking into account that some vector genomes may pair with each other to create double-stranded molecules.
Transduction of cells. AAV vectors transduce many types of cultured cells, and all that is necessary is to add vector directly to the cell culture medium. We typically plate cells the day before infection to ensure a consistent cell number and density. Vector dose is determined by the number of genome-containing particles per cell, which can range from hundreds to many thousands. If using an antibiotic resistance gene, the antibiotic selection should not be commenced earlier than 24 h after infection, and typically at least 48 h later, to allow the transgene to be adequately expressed. The minimum lethal dose for the antibiotic varies depending on the cell type and should be empirically determined using a kill curve. A negative control of untransduced cells should always be included in parallel. In addition, a dish with 0.5% (somatic cells) or 5% (ESCs/iPSCs) of infected cells should be grown without selection, to determine the total number of colony-forming units (CFUs) plated. A special consideration for PSCs is their poor plating efficiency, particularly when passaged as single cells. Because of this, more transduced colonies can be obtained if cultures are not manipulated after infection until colonies are visible and picked. Somatic cells can be passaged as early as 1 d after infection, and replated to the appropriate size dishes for colony selection. This allows one to infect in a smaller volume, which results in more effective vector delivery.
Once drug-resistant colonies appear, these can be counted and/or isolated for further expansion and analysis. The transduction frequency equals the total number of drug-resistant CFUs obtained from a single infection divided by the total number of unselected CFUs from the same infection. Total CFU numbers can be obtained from colony counts by correcting for the fraction of cells plated with and without selection. Importantly, the drug-resistant colonies may include both targeted clones and clones with randomly integrated vector genomes. Therefore, to determine the targeting frequency, the fraction of drug-resistant colonies that are targeted must also be established (see below). The absolute targeting frequency can then be expressed as the total number of targeted CFUs per infection divided by the total number of unselected CFUs. The targeting frequency can also be expressed as the fraction of drug-resistant colonies that are targeted; however, this number is highly dependent on vector design and does not accurately assess the proportion of cells undergoing HR.
Targeting can be demonstrated conclusively by analyzing genomic DNA from expanded, transduced colonies. The most definitive proof is a Southern blot using a restriction enzyme with at least one recognition site outside the homology region and a genomic probe outside the homology region as well (example in Fig. 2 ). This ensures that only the chromosomal target locus is detected and not random integrants. The probe should be 500-1,000 bp in size and free of repeated sequences, as determined by RepeatMasker. A separate vector-specific probe such as the selectable marker gene should be used to confirm targeting and detect random integration events (typically < 5% of targeted clones contain additional random integrants, reflecting the frequency of random integration in the total cell population). DNA from the parental, untargeted cell line should always be included as a control in Southern blots. Concatamerized vector multimers can integrate at the target locus 16 ; accordingly, one should assay both sides of the targeted locus with specific restriction enzymes and/or probes for a complete characterization. PCR can also be used to identify targeted clones and with appropriate controls can be quite reliable. Typically, one primer lies in the vector selectable marker and the other in flanking chromosomal DNA outside the homology region. However, once targeted clones are identified, we recommend confirming PCR results with Southern blots. When analyzing fewer than 50 clones, it is often quicker to just perform Southern blots.
MaterIals

REAGENTS
293T cells 61 2 O. Sterilize by passing through a 0.22-µm filter and store in 2-ml aliquots at 4 °C. Cell lysis buffer (for AAV stock preparation) Add 3 ml of 5 M NaCl and 5 ml of 1 M Tris-HCl (pH 8.5) to 80 ml of dH 2 O. Adjust the pH to 8.5 with NaOH and adjust the volume to 100 ml with dH 2 O. Sterilize by passing through a 0.22-µm filter and store at 4 °C. Church buffer Combine 500 ml of 1 M phosphate buffer (pH 7.2), 2 ml of 0.5 M EDTA, 10 g BSA and 70 g SDS in a final volume of 1 liter with dH 2 O. Store at room temperature (25 °C). Coomassie blue stain Combine 1.5 g Coomassie Brilliant Blue G, 300 ml methanol and 100 ml glacial acetic acid in a final volume of 1 liter with dH 2 O. Store at room temperature. D10 (DMEM with 10% FBS (vol/vol)) Combine 500 ml of DMEM high glucose with 50 ml of FBS, 5 ml of penicillin/streptomycin and 2.5 ml of amphotericin B (final concentration, 1.25 µg ml ESC medium Combine 500 ml of F12/DMEM, 100 ml of KSR, 6 ml of penicillin/streptomycin, 6 ml of sodium pyruvate, 6 ml of nonessential amino
acids, 0.6 ml of 0.1 M β-mercaptoethanol and 0.3 ml of a 4-µg ml − 1 bFGF solution. Sterilize by passing through a 0.22-µm filter and store at 4 °C. Use within 2 weeks. ESC wash medium Add 50 ml of KSR to 500 ml of DMEM high glucose. There is no need to filter sterilize as both components are sterile. Store at 4 °C for up to 2 months. Gelatin (0.1% (wt/vol)) Dissolve 5 g of gelatin in 1 liter of dH 2 O to prepare 0.5% stock solution, sterilize by autoclaving and store at room temperature. Prepare a 0.1% gelatin working solution as a 1:5 dilution of the 0.5% stock in sterile dH 2 . To dissolve the DNA, stir the solution for at least 2-4 h at room temperature. Adjust the concentration of NaCl to 0.1 M and extract the solution once with phenol and once with phenol/chloroform. Recover the aqueous phase and shear the DNA by passing the solution rapidly 12 times through a 17-gauge needle. Precipitate using ethanol, centrifuge and dissolve at a concentration of 10 mg ml 2| After 3 d, aspirate the medium and wash the dish with 2 ml of 1× PBS. Add 2 ml of trypsin-EDTA solution and incubate at 37 °C for 2 min or until cells detach from culture dish.
3| Add 4 ml of D10 to neutralize trypsin-EDTA solution and transfer the cell suspension to a 15-ml conical tube.
4|
Centrifuge at 250g for 5 min at 20 °C in a tabletop centrifuge.
5|
Resuspend the cells in 1 ml of D10. Take a 10-µl aliquot and count the cells using a hemocytometer.
6|
Adjust cell concentration to 10 6 cells per ml with D10 and plate 1 ml of cell suspension in eight 10-cm dishes, each containing 10 ml D10. Culture for 72 h in a 37 °C incubator with 5% CO 2 atmosphere.
7|
After the 3-d incubation, harvest cells as described in Steps 2-4. Resuspend in 5 ml of D10 and take a 10-µl aliquot for counting with a hemocytometer. Adjust cell concentration to 4 × 10 6 cells per ml and plate 1 ml of cell suspension in 30 10-cm dishes, each containing 10 ml D10. Incubate in a 37 °C incubator overnight.
8|
The next day, prepare solution A by combining 15.5 ml of 2× HEPES-saline and 155 µl of 0.15 M phosphate buffer in a 50-ml tube and, mixing well.
9|
In another 50-ml tube, prepare solution B by combining 1.938 ml of 2 M CaCl 2 , 387.5 µg of plasmid pDG, 387.5 µg of AAV vector plasmid (prepared as described in Box 2) and water to a final volume of 15.5 ml. Mix well.
Box 2 | AAV VECToR PLAsMID CoNsTRuCTIoN
A protocol for the construction of AAV targeting vector plasmids is also mentioned in Rago et al 65 . The method described below differs from theirs in several ways, including sequential ligation reactions for the homology arms and selection cassette, instructions for PCR amplification of the homology arms that avoid amplification-induced errors and suggestions for screening plasmids and quantifying the inverted terminal repeat (ITR) deletions that inevitably occur. The vector plasmid sequence and status of its ITRs may influence the function of the vector stocks that are produced with it. The protocol below describes the assembly of a vector plasmid designed to insert a loxP-flanked selection cassette and produce a functional knockout of the target gene. 1. Prepare the AAV vector backbone by digesting 5 µg of plasmid pAAV-MCS with NotI restriction enzyme and gel-purifying the backbone fragment with the QIAquick Gel Extraction Kit according to the manufacturer's instructions. 2. Dephosphorylate the digested backbone using 0.5 U CIP per µg of DNA at 37 °C for 1 h. 3. The vector backbone is extracted using phenol-chloroform, precipitated using ethanol and resuspended in 50 µl of TE. 4. Amplify the selection marker cassette using 5′ and 3′ oligos designed to include loxP sites and restriction sites compatible with the homology arms. A polyadenylation signal should be included outside the loxP site on the reverse oligo, and a sequence with a stop codon in all three reading frames should be placed outside the loxP sites on the forward oligo. 5. Run the amplified selection cassette on 0.8% (wt/vol) agarose gel in 1× TAE buffer and extract the desired fragment using QIAquick Gel Extraction Kit. 6. Design primers for the amplification of homology arms. We amplify the 5′ and 3′ homology arms in separate PCR reactions from the cell line to be used in the targeting experiment. The forward oligo for the 5′ homology arm and the reverse oligo for the 3′ homology arm are designed to have a NotI site for insertion into the AAV vector backbone. The reverse oligo for the 5′ homology arm and the forward oligo for the 3′ homology arm should have appropriate restriction sites for ligating to the selection marker fragment. 7. Set up three independent PCR reactions for the amplification of each homology arm using TURBO Taq polymerase, as described below. This is to avoid PCR errors. Run the products from the three independent PCR reactions separately on 0.8% (wt/vol) agarose gel in 1× TAE buffer and gel-extract the homology arms with the QIAquick Gel Extraction Kit. 10. Clone the gel-eluted PCR products from each of the three separate PCR reactions into pGEM-T Easy Vector using the pGEM-T Easy Vector system I kit according to the manufacturer's instructions. 11. Sequence at least one clone from each independent PCR reaction. When the exact same sequence is recovered at least twice, PCR errors can be ruled out and this sequence must be present at a minimum of one target locus allele. Choose this sequence for incorporation into the vector plasmid. New SNPs can sometimes be identified this way. 12. Digest the plasmids containing cloned homology arms with the appropriate restriction enzymes for vector construction and gelpurify these fragments.
(continued)  crItIcal step Use a 10-ml pipette and tilt the dish so that the 1.0 ml of transfection mix is added to a greater depth of medium to prevent 'blasting' cells off the dish.
11|
Agitate the dishes gently to evenly distribute the precipitate and return the dishes to the 37 °C incubator.
12| Observe a dish 1 h later under a microscope. The precipitate should be visible as small grains about the size of bacteria.
Return the dishes to the 37 °C incubator.
13| After 48 h, prepare dry ice/ethanol bath by placing a centrifuge tube rack in a styrofoam container. Add ~2 lbs of dry ice, pour 2 liters of ethanol over it and cover the container.
14|
Collect the cells and medium by scraping the cells off the dish with a rubber policeman and transferring it to a 50-ml conical tube. We use Corning 50-ml conical tubes, as they are more resistant to the subsequent freeze-thaw cycles. Rinse dishes with 5 ml of 1× PBS and transfer it to the same conical tube. Harvest four dishes at a time into the same 50-ml tube.
15|
16|
Aspirate the medium from the conical tube and repeat Steps 14-15 until cells are pelleted from all 30 dishes. The same tube can be used for pelleting cells from all the dishes.
Box 2 | (CoNTINuED)
13. Set up a three-way ligation reaction with the AAV vector backbone (30 ng) and the 5′ and 3′ homology arms using T4 DNA ligase according to the manufacturer's instructions. A control ligation with only the AAV vector backbone should also be set up. The vector backbone and homology arm DNAs should be in a 1:3:3 molar ratio in the ligation reaction.  crItIcal step The homology arms and the vector backbone should have compatible sticky ends for the ligation to be successful. 14. Electroporate 2 µl of the ligation mix as well as the control mix separately into 50 µl of electrocompetent DH10B cells. Immediately add 500 µl of SOB medium to the electroporation cuvette, transfer to a 14-ml tube and incubate at 37 18| Freeze the pellet in the dry ice/ethanol bath and thaw in a 37 °C water bath.
19| Repeat
Step 18 twice and store at − 80 °C.  pause poInt The pellet can be stored at − 80 °C indefinitely and thawed at your convenience.
20|
Thaw cell lysate in a 37 °C water bath.
21|
Add Benzonase to the cell lysate at a final concentration of 50 U ml − 1 . Benzonase is added to eliminate cellular DNAs/RNAs as well as excess plasmid DNAs present during transfection.
22|
Incubate at 37 °C in a water bath for 30 min. Prepare iodixanol gradient (refer to Box 3) during the incubation.
23|
Centrifuge at 5,000g for 30 min at 4 °C in a Sorvall high-speed centrifuge using an HS-4 rotor.
24|
Collect vector-containing supernatant. The volume of the supernatant is approximately 5 ml.
25|
Load the 5 ml of vector-containing supernatant over the iodixanol density gradient prepared in Step 22. Top off the tube with cell lysis buffer. This density gradient purification step can remove contaminants that may influence transduction and targeting frequencies.
26|
Centrifuge at 461,300g for 1 h at 18 °C with maximum acceleration and deceleration in a Beckman Ti70 rotor on a Beckman ultracentrifuge; use proper spacers for tubes.
27|
Puncture the tube on the side slightly below (3-5 mm) the 60-40% interface with an 18-gauge needle (bevel up) attached to a 10 ml syringe.
28| Collect 3-4 ml from each centrifuge tube by aspiration using the same needle.  crItIcal step Avoid the proteinaceous material near the 40-25% interface.
29|
To use the vector without removing iodixanol, proceed directly with Step 30; iodixanol is inert and non-toxic to cells. Alternatively, further purify Serotype 2 vector stocks over a HiTrap heparin affinity column, followed by desalting over a HiTrap desalting column as described in Box 4, before proceeding with Step 30. aaV titering using neutral gel electrophoresis and southern blotting • tIMInG 4 d 30| To prepare plasmid standards for quantitation, digest the same vector plasmid used to prepare the stock, such that the vector genome is released from the surrounding inverted terminal repeats. Set up the restriction digest by adding the following to a microcentrifuge tube: restriction buffer (10×, 2 µl); plasmid DNA (1,000 ng); restriction enzyme (5 U); and dH 2 O to a final volume of 20 µl.
31|
Incubate the restriction digest in a 37 °C water bath for 1 h. Stop the reaction by adding 2 µl of 0.5 M EDTA.
32| Run 2 µl of the restriction digest on a 1% (wt/vol) agarose gel to confirm that the plasmid is completely digested.
33|
Accurately quantify the digested DNA content by using a fluorometer and make serial dilutions as follows: 100, 30, 10 and 3 pg µl 34| Prepare 1% (wt/vol) agarose gel in 1× TAE. Allow it to set at room temperature for 1 h.
35|
Label four microcentrifuge tubes as 1,000, 300, 100 and 30 pg. Pipette out 10 µl from each standard dilution into the appropriate tube.
Box 4 | PuRIFICATIoN oF AAV2 sToCKs BY HEPARIN AFFINITY CoLuMN
FoLLoWED BY DEsALTING 1. Remove the top cap from the HiTrap heparin affinity column and add a few drops (~200 µl) of PBS-MK buffer to the top of the column to avoid air bubbles. 2. Connect the HiTrap Luer adaptor to the top of the column. Some of the buffer will overflow; absorb this with Kimwipes. 3. Add a few drops (~100 µl) of PBS-MK buffer to the top Luer adaptor. 4. Place the 10 ml syringe with 10 ml PBS-MK buffer into the Luer adaptor. 5. Remove the bottom and snap it off. 6. Wash the column with PBS-MK buffer. It takes ~8 min to deliver 10 ml PBS-MK.  crItIcal step Air bubbles must be removed from the liquid in the syringe at all steps before pushing it through the column, as they tend to impede flow. Do not exceed a flow rate of 4 ml min − 1 .  crItIcal step Each time a step is completed, replace the bottom cap before you remove the syringe from the column, then remove the syringe and add 100 µl of PBS-MK buffer to the Luer adaptor. When the syringe is placed in the Luer adaptor for the next step, remove the bottom cap. 7. Load the column using the 10-ml syringe containing the iodixanol fraction (from Step 29 of PROCEDURE). Use a syringe pump and rate of 20 ml h − 1 . Reserve approximately 25-30 µl before loading on the column for quantitation. 8. Collect the flow-through in a 14-ml tube. 9. Wash column with 5 ml of PBS-MK buffer using a syringe pump at the rate of 20 ml h − 1 . 10. Collect the flow-through in a 14-ml tube. 11. Elute vector from the column with 2.4 ml of 1 M NaCl/PBS-MK buffer. 12. Collect the first 0.4 ml in a microcentrifuge tube. This is the 'void volume' . 13. After this initial 0.4-ml void volume, collect the following fractions: fraction 1 is 1 ml, fraction 2 is 0.5 ml and fraction 3 is 0.5 ml. The vector should come off the column in the first 1.5 ml (fractions 1 and 2). 14. Desalt after the heparin affinity column purification with a HiTrap desalting column. Wash the HiTrap desalting column with 25 ml of DMEM (or other medium/buffer) in a 30-ml syringe.  crItIcal step Do not exceed a flow rate of 5 ml min − 1 .
Prepare the following:
A 3-ml syringe containing 1.5 ml of fractions 1 and 2. A 3-ml syringe containing 3 ml of DMEM high glucose (or other medium/buffer to be used when transducing cells). 16. Position the column to collect fractions into microcentrifuge tubes: the first tube for the 1.5 ml of void flow-through, then 'exchange' fractions X1-X3 (1 ml each). 17. Load the 1.5 ml of vector into the 3-ml syringe. 18. Quickly load the 3 ml of DMEM high glucose or other medium in the second 3-ml syringe. 19. The vector should be in fractions X1 and X2. Pool fractions X1 and X2 and make 10 aliquots of 200 µl each (or other aliquot sizes) in microcentrifuge tubes. Prepare 1:10 and 1:100 dilutions of the AAV stock in TE buffer for determining titer later.  pause poInt The vector stock and dilutions can be stored at -80 °C indefinitely. If necessary, store stocks in small aliquots and avoid repeated freezing and thawing. 36| Take the AAV stock out of the − 80 °C freezer and thaw at room temperature.
37|
Prepare two microcentrifuge tubes, each containing 3 µl of TE and 1 µl of 6× loading dye. Add 2 µl of the 1:10 vector stock dilution to the first tube and 2 µl of the 1:100 stock dilution to the other (dilution preparation described in step 19, Box 4).
38|
Clip the AAV stock tubes tightly.
39|
Boil them for 2.5 min, snap-cool quickly on ice.  crItIcal step The vector is boiled to disrupt its capsid and to release the single-stranded DNA genome before loading it onto a neutral gel.
40|
Load the standards and AAV stock dilutions along with λ/HindIII marker on the 1% (wt/vol) agarose gel and run at 120 V for 4 h. 
42|
Transfer the gel to a tray and acid-depurinate with 500 ml of 0.25 M HCl for 10 min, twice. Rock the gel gently.
43|
Remove the HCl solution and neutralize with 500 ml of 0.4 M NaOH for 15 min, twice. Rock the gel gently.
44|
Transfer to a Hybond-XL membrane with 1 liter of 0.4 M NaOH overnight using standard Southern blot wicking methods 63 .
45|
The next day, briefly rinse the membrane in 2× SSC.
46| UV crosslink the membrane on a UV Stratalinker (auto-crosslink setting).  pause poInt The membrane can be stored at 4 °C, wrapped in plastic wrap, for several months.
47|
Prehybridize the membrane with 14 ml of Church buffer containing 150 µg ml − 1 of salmon sperm DNA (boiled for 5 min and snap-chilled on ice) for 3-4 h in a hybridization cylinder rotating in a hybridization incubator at 65 °C.
48| Synthesize a radiolabeled probe by random priming with a Rediprime II kit according to the manufacturer's instructions. ! cautIon Follow all relevant institutional guidelines while working with radioactivity. Radioactive probe must be prepared in a fume hood. Wear protective clothing including gloves, plastic shield and safety glasses.
49|
Purify the radiolabeled probe with a ProbeQuant G-50 microcolumn. Denature it by boiling for 5 min and snap-cool on ice.  crItIcal step Use screw cap tubes for boiling to prevent leakage of radioactive probe.
50|
Add the denatured probe to the prehybridization solution and incubate at 65 °C overnight in the hybridization oven.
51|
The following day, remove the radioactive hybridization solution and dispose of it properly. Wash the hybridized membrane twice with 45 ml of Southern wash solution 1 for 15 min at 65 °C in a hybridization cylinder. ! cautIon Follow institutional guidelines while working with radioactivity. The radioactive waste must be discarded in the designated radioactive waste disposal container. Wear protective clothing including gloves, plastic shield and safety glasses.
52|
Wash the membrane twice with 45 ml of Southern wash solution 2 for 15 min at 65 °C in a hybridization cylinder.
53|
Expose the membrane to X-ray film at − 80 °C overnight. Develop the X-ray film on a Kodak 480 RA processor. This provides a visual record of the stock titer. 55| Generate a standard curve based on the radioactive signal of the standard dilutions and determine the vector titer. The radioactive signal from the vector sample(s) should fall within the standard curve and can be used to calculate the 71| Invert and drain the tube on a clean absorbent paper and allow to air-dry for 10 min.  crItIcal step The pellet may not be very tight; drain the ethanol gently, taking care not to disturb the pellet at the bottom.
72|
Add 100 µl of TE buffer. Hydrate the DNA by incubating at 65 °C for 1 h and overnight at room temperature.  pause poInt For long-term storage, store at − 20 °C. Half of the restriction enzyme can be added at the beginning and the other half can be added after 4 h.  pause poInt The restriction digests can be stored at − 80 °C and heated to 56 °C for 3 min before loading.
74| Pour an 0.8% (wt/vol) agarose gel in 1× TAE, and load 5 µg of the digested samples after mixing with the loading dye.  crItIcal step High-molecular-weight genomic DNA is sometimes not uniformly distributed in TE, which can lead to inaccurate measurement before digestion. Thus, the digested DNA samples need to be requantitated on a fluorometer before loading onto the gel. λ/HindIII DNA can be used as size markers.
75|
Run the gel at 120 V for 4-5 h in 1× TAE buffer. 
76|
